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Abstract Cardiomyocytes use glucose as well as fatty
acids for ATP production. These substrates are transported
into the cell by glucose transporter 4 (GLUT4) and the fatty
acid transporter CD36. Besides being located at the sar-
colemma, GLUT4 and CD36 are stored in intracellular
compartments. Raised plasma insulin concentrations and
increased cardiac work will stimulate GLUT4 as well as
CD36 to translocate to the sarcolemma. As so far studied,
signaling pathways that regulate GLUT4 translocation
similarly affect CD36 translocation. During the develop-
ment of insulin resistance and type 2 diabetes, CD36
becomes permanently localized at the sarcolemma,
whereas GLUT4 internalizes. This juxtaposed positioning
of GLUT4 and CD36 is important for aberrant substrate
uptake in the diabetic heart: chronically increased fatty
acid uptake at the expense of glucose. To explain the dif-
ferences in subcellular localization of GLUT4 and CD36 in
type 2 diabetes, recent research has focused on the role of
proteins involved in trafficking of cargo between subcel-
lular compartments. Several of these proteins appear to be
similarly involved in both GLUT4 and CD36 translocation.
Others, however, have different roles in either GLUT4 or
CD36 translocation. These trafficking components, which
are differently involved in GLUT4 or CD36 translocation,
may be considered novel targets for the development of
therapies to restore the imbalanced substrate utilization
that occurs in obesity, insulin resistance and diabetic
cardiomyopathy.
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Introduction
We previously reported that known signaling mechanisms,
such as insulin and contraction, similarly affect myocyte
GLUT4 and CD36 trafficking [1]. However, in insulin
resistance and type 2 diabetes CD36 permanently relocates
to the sarcolemma, while GLUT4 internalizes [2, 3]. As a
corollary there must be mechanisms which selectively
recruit either GLUT4 or CD36. Therefore, we began to
investigate distinct intracellular processes involved in
vesicular transport to uncover mechanisms that are differ-
ently involved in GLUT4 and CD36 trafficking [4, 5].
We revealed coat-proteins, actin filaments, the cellular
pH gradient and vesicle-associated membrane proteins
(VAMPs) to be involved in GLUT4 and CD36 trafficking,
and, importantly, indeed found mechanisms that are dif-
ferently involved in glucose and fatty acid uptake in
cardiomyocytes.
In this review, we first describe how cardiac glucose and
fatty acid uptake are regulated and which alterations occur
during insulin resistance and type 2 diabetes. Then, we
address signaling pathways and subcellular trafficking
components that are involved in GLUT4 and CD36 trans-
location. Finally, we focus on components that are
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differently involved in glucose and fatty acid uptake and
describe novel targets to restore metabolic disturbances in
type 2 diabetes.
Regulation of cardiac glucose and fatty acid uptake
Glucose and fatty acids are of fundamental importance for
energy production in all eukaryotic cells. In cardiomyo-
cytes, the continuous supply of both substrates is especially
crucial to maintain contractile activity [6]. Cardiomyocytes
are metabolically flexible, i.e., they preferably use fatty
acids, but can also use glucose, ketone and lactate to pro-
duce ATP [7]. These different substrates cannot sufficiently
enter cardiomyocytes by diffusion and thus have to be
taken up by facilitated transport. Glucose uptake into cells
involves a family of glucose transport proteins—called
GLUTs—which shuttle sugars across plasmalemmal
membranes through their aqueous pore [8]. The GLUT
family consists of several members which are expressed by
various cell types [9]. In cardiomyocytes, GLUT family
members 1 and 4 fulfil this function. While GLUT1 is
mainly involved in basal glucose uptake, GLUT4 translo-
cates to the plasma membrane to enhance glucose uptake in
response to extracellular stimuli like insulin or increased
cardiac work. Cellular fatty acid uptake is facilitated by
several membrane proteins with high-affinity binding sites
for fatty acids [1], but the exact mechanisms by which
these proteins mediate transmembrane passage of fatty
acids is not known [10]. In cardiomyocytes, the most
important fatty acid transporters are fatty acid translocase
(FAT), also referred to as CD36 [10, 11], and two members
of the family of 6 fatty acid transport proteins (FATP), i.e.,
FATP 1 [12] and 6 [13].
Both GLUT4 and CD36 are integral membrane proteins.
GLUT4 consists of 12 transmembrane domains with both
termini in the cytoplasm and one large intracellular and one
large extracellular loop [14]. CD36 has a hairpin-like
structure with two transmembrane regions and both the
C-terminal and N-terminal tails in the cytoplasm [1]. The
translocation of both proteins from intracellular storage
compartments to the plasma membrane, and vice versa,
relies on a complex trafficking system, schematically rep-
resented in Fig. 1 [15]. Immunoadsorption studies in rat
cardiomyocytes showed that GLUT4 resides in two distinct
pools, one of which is called GLUT4 storage vesicles
(GSV) that does not contain CD36 and is sensitive to
insulin [16]. On the other hand, CD36 appears to reside in
one subcellular pool which does not contain GLUT4 [16],
suggesting that GLUT4 and CD36 are stored separately and
travel independently.
Physiological stimuli, with circulating plasma insulin
concentrations and increased cardiac work being the most
important, stimulate the heart to quickly alter cardiac
substrate utilization via reversible translocation of GLUT4
and CD36 from intracellular membrane compartments to
the sarcolemma (Fig. 2a) [1, 10]. In contrast to CD36, the
other fatty acid transporters FATP1 and FATP6 do not
traffic between intracellular storage compartments and the
sarcolemma in cardiomyocytes [17–19]. Therefore, FATP1
and FATP6 do not contribute to inducible fatty acid uptake.
In addition, other studies have disclosed that these trans-
porters also have a minor contribution to basal fatty acid
uptake. From experiments with cardiomyocytes from wild-
type and CD36 null mice, it is known that the contribution
of CD36 to fatty acid uptake is about 70% [17]. In addi-
tion, in cardiomyocytes treated with the specific CD36
inhibitor sulfo-N-succinimydyl-oleate (SSO), the insulin/
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Fig. 1 The endomembrane system of cardiomyocytes consists of
several functionally different compartments. In the translocation
process (red arrows) proteins are synthesized in the endoplasmic
reticulum and further modified in the Golgi apparatus. There, the
budding of transport vesicles occurs and vesicles are transported to
the endosomal system. GLUT4 is further transported to specific
insulin-responsive GLUT4 storage vesicles (GSV). GLUT4 and
CD36 can be stimulated to translocate from their compartments to
the sarcolemma. In the endocytosis process (blue arrows), sarcolem-
mal proteins are taken up into the cell again and transported through
the early endosomes and directed towards lysosomes for protein
breakdown or towards the recycling endosomes for renewed use at the
sarcolemma
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contraction-mediated increase in fatty acid uptake was
totally blocked, meaning that CD36 is irreplaceable in
stimulus-induced fatty acid uptake [20]. The system of
regulated substrate uptake is crucial during exercise to
supply cardiomyocytes with a sufficient amount of sub-
strates, or to quickly replenish intracellular substrate
storage pools after a meal. A dysfunction in this system of
regulated glucose and fatty acid uptake into muscle, adi-
pose tissue, beta cells and heart contributes to the
development and progression of type 2 diabetes [10, 21].
The amount of glucose and fatty acid transporters
present at the sarcolemma is a major regulatory factor of
cardiac glucose and fatty acid utilization [22]. This impli-
cates that the metabolic machinery is more than adequately
suited to process all incoming substrates. Accordingly,
intracellular concentrations of fatty acids and glucose will
remain low. This is also true for the diabetic heart in which
intracellular concentrations of these substrates are not
markedly increased [1, 23]. Hence, in both the healthy and
the diabetic heart, the sarcolemmal presence of GLUT4
and CD36 determines cardiac substrate flux [24].
Alterations in transporter location in insulin resistance
Obesity, insulin resistance and type 2 diabetes show a
strong association with changes in lipid metabolism [2, 25].
Permanent relocation of CD36 to the sarcolemma and
increased fatty acid uptake were strongly linked in rodent
models for insulin resistance [2, 26, 27] and obese humans
[26, 28, 29]. Furthermore, the sarcolemmal content of
CD36 correlated well with increased uptake of fatty acids,
increased intramuscular triacylglycerol [28, 30, 31] and
reduced insulin-stimulated GLUT4 translocation and glu-
cose uptake [32]. Cardiac in vivo positron-emission
tomography (PET) in humans with type 2 diabetes showed
increased fatty acid uptake and oxidation, and reduced
insulin-stimulated glucose uptake, paralleled by decreased
diastolic function as compared to age-matched healthy
controls [33].
The increase in intramyocardial lipid concentrations
cannot just be attributed to a reduction in mitochondrial
fatty acid oxidation, since studies have shown that cardiac
fatty acid oxidation remained unchanged, slightly reduced,
or even increased in several rodent models of obesity and
insulin resistance [10]. Inhibition of CD36-mediated fatty
acid uptake with SSO normalized fatty acid utilization in
different rodent models of insulin resistance [26]. This
indicates that the increase in intramyocardial lipid con-
centrations in insulin-resistant cardiomyocytes is caused by
increased CD36-mediated fatty acid uptake. We and others
showed that the surface presence of CD36 was increased in
rodent models for insulin resistance and in skeletal muscle
of obese humans [2, 3, 32]. The increase in surface pres-
ence of CD36 is not due to increased tissue expression, but
instead to a permanent relocation from its intracellular
storage compartment. This permanent CD36 relocation
appears to be an early event in the sequence of maladaptive
changes in the hearts of rodents with type 2 diabetes. We
also obtained evidence that there is no decrease in cardiac
mitochondrial function in this early pre-diabetic stage.
However, it is very well possible that mitochondrial dys-
function develops at later stages which can lead to even
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Fig. 2 Alterations in transporter localisation in diabetic cardiomyo-
cytes compared to healthy cardiomyocytes. a Substrate uptake in
healthy cardiomyocytes. The entry of glucose and fatty acids is
facilitated by glucose transporter 4 (GLUT4) and fatty acid
transporter CD36. The heart can acutely react to a change in energy
demand by reversible translocation of these transporters from
intracellular storage compartments. Once these substrates have
entered the cell they can be used for ATP production by mitochon-
drial oxidation or they can be stored as glycogen (not shown) or in
lipid droplets. b Substrate uptake in diabetic cardiomyocytes: during
the development of insulin resistance and type 2 diabetes, the
localisation of GLUT4 and CD36 permanently alters. CD36 presence
at the sarcolemma increases which associates with increased fatty
acid uptake. In addition, fatty acid storage increases which is thought
to interfere with insulin-stimulated glucose uptake
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more lipid storage. Moreover, it has been shown that
relocation of CD36 was specific for this fatty acid
transporter because such changes were not observed for
plasmalemmal FABPpm, FATP1 or FATP4 [10]. Thus,
permanent relocation of CD36 to the sarcolemma is
important in the development toward diabetic cardio-
myopathy.
It is becoming evident that the increased intramyocar-
dial triacylglycerol content is not the main contributor to
the development of insulin resistance and cardiac dys-
function. Other lipid metabolites, such as ceramides and
diacylglycerols, appear to be the main contributors to
reduced insulin sensitivity (see [34, 35] for excellent
reviews on this topic).
Collectively, obesity, insulin resistance and type 2 dia-
betes impose metabolic stress on the heart [36–39], which
may ultimately lead to cardiac metabolic inflexibility,
lipotoxicity, and subsequent development of diabetic car-
diomyopathy [3, 32] (Fig. 2b).
Signaling pathways involved in GLUT4 and CD36
translocation
As mentioned above, postprandial increases in circulating
plasma insulin levels and an elevated cardiac work are the
most important physiological stimuli to enhance cardiac
glucose and fatty acid uptake via induction of GLUT4 and
CD36 translocation, respectively [1]. However, the meta-
bolic fates of glucose and fatty acids are quite different
during insulin-stimulation versus contraction-stimulation.
Both substrates are preferentially stored under insulin-
stimulated conditions, and preferentially oxidized upon
increased contraction [1]. Since translocation of GLUT4
and CD36 are similarly induced by insulin and contraction,
these translocation processes do not contribute to the dif-
ferent metabolic fates of both substrates during insulin-
versus contraction-stimulation. Rather, upon intracellular
trapping of both substrates [glucose via hexokinase and
fatty acids via acetyl-CoA synthase (ACS)], the metabolic
fates of glucose and fatty acids are determined by the
activation state of key metabolic enzymes. Specifically,
glucose and fatty acids are directed towards storage via
insulin-induced activation of glycogen synthase (GS) and
glycerol-3-phosphate acyltransferase (GPAT), respectively
[1]. In addition, the contraction-induced drop in the intra-
cellular ATP concentrations triggers phosphofructokinase,
pyruvate dehydrogenase and TCA cycle progression for
acceleration of glucose oxidation, and also carnitine-pal-
mitoyl transferase-1 for acceleration of fatty acid oxidation
[1]. Despite differential effects of insulin and contraction
on the metabolic machinery, both stimuli similarly induce
translocation of GLUT4 and CD36 to the sarcolemma [1].
This similarity in responsiveness of both transporters to
both physiological stimuli suggests that similar signaling
mechanisms are involved in GLUT4 and CD36 transloca-
tion. In addition, it suggests that GLUT4 and CD36 migrate
together to the sarcolemma in response to each of the
stimuli. However, increasing numbers of studies report
differences in the regulation of both substrate transporters,
leading to a more differentiated understanding of GLUT4
and CD36 traffic.
Exactly how insulin and increased workload achieve
increased abundance of GLUT4 and CD36 at the sarco-
lemma is unclear, but there are two primary candidates:
increasing exocytosis or inhibiting endocytosis [40–43].
Insulin is proposed to stimulate fusion of intracellular
GLUT4 containing-vesicles with the plasma membrane in
cardiac and skeletal myocytes while it does not affect the
rate of endocytosis [42, 44, 45]. In myocytes, fusion of
intracellular membranes with the plasmalemmal membrane
is considered to be inducible, while endocytosis of GLUT4
and CD36 is regarded a housekeeping process which can-
not be regulated. However, it has been reported that
decreased endocytosis in response to insulin regulates
GLUT4 translocation in adipocytes [46]. Some studies
found that, in line with the effect of insulin on GLUT4
translocation, contraction increases GLUT4 translocation
[44, 45]. In contrast, another study found that GLUT4
endocytosis is inhibited [42]. In summary, the exact
mechanism by which insulin and contraction increase
presence of CD36 and GLUT4 at the plasma membrane
requires further studies aiming at the rate of endocytosis
and/or the rate of translocation.
Insulin-signaling
From all stimulus-induced transporter translocation pro-
cesses, insulin-induced GLUT4 translocation is the most
intensively studied [47]. Several of the kinases involved in
insulin-induced GLUT4 translocation have been tested on
their additional involvement in insulin-induced CD36
translocation. So far, these kinases seem to play a similar
role in both translocation events, as detailed below. The
insulin-signaling axis is initiated by the binding of insulin
to its receptor and subsequent activation of insulin receptor
substrate (IRS) 1 [48] and IRS2 [49] (Fig. 3a). These
activate the regulatory subunit of phosphatidylinositol-3-
kinase (PI3K), which consists of a catalytic p110 subunit
and a regulatory p85 subunit [50]. Pharmacological
inhibitors (most notably wortmannin) have greatly facili-
tated the investigation of the role of PI3K in GLUT4 and
CD36 translocation, and have pinpointed this lipid kinase
as a key component [51–53]. The main phosphatidylino-
sitol (PI)-phosphate generated by PI3K during insulin
action is PI-3,4,5-trisphosphate (PIP3) [54]. Generation of
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PIP3 at the plasma membrane directly drives the activation
of a number of different protein kinases with lipid binding
pleckstrin homology domains [55]. Three of these kinases
play an essential role in insulin-induced glucose uptake: (1)
Akt/protein kinase B (PKB)-isoform 2, (2) protein kinase C
(PKC)-k/f and (3) 3-phosphoinositide-dependent protein
kinase (PDK) [56–59]. Akt/PKB-2 and PKC-k/f have
additionally been implicated in insulin-induced CD36
translocation [24, 59].
Activation of Akt requires dual phosphorylation at Ser473
and Thr308 in addition to PI3K-mediated recruitment to the
plasma membrane [1]. The Thr308 phosphorylation within
the activation loop of Akt is mediated by PDK1 [60] and the
Ser473 phosphorylation by a putative PDK2 [61]. Upon its
activation, Akt phosphorylates TBC1D1 and TBC1D4, also
referred to as AS160, as a final step to induce GLUT4
translocation [62, 63]. Next to Akt, PDK1 also activates
PKC-f upon unfolding of its pseudosubstrate domain and
exposure of the activation loop [64]. The simultaneous and
combined activation of Akt and PKC-k/f is necessary for
insulin-induced GLUT4 translocation in both heart [65] and
skeletal muscle [66], and likely also essential for insulin-
induced CD36 translocation.
To date, GLUT4 and CD36 translocation seem identi-
cally regulated by insulin. However, it is possible to
translocate GLUT4 from insulin-responsive intracellular
compartments in cardiomyocytes without changes in sub-
cellular CD36 localization using the thiol-modifying agent
arsenite [67]. Hence, there are arsenite-sensitive proteins
that contribute to insulin-induced GLUT4 translocation
without affecting CD36 dynamics.
Contraction-signaling
Increased cardiac work results in a rapid rise of both glu-
cose and fatty acid uptake in heart and muscle [1, 68].
Upon increased contraction, the intracellular concentration
of adenosine-monophosphate (AMP), cyclic AMP, reactive
oxygen species (ROS) and calcium increase. Together,
these second messengers activate a complex signaling
system that involves AMP-activated protein kinase
(AMPK), protein kinase A (PKA), atypical PKCs, protein
kinase D (PKD), calcium–calmodulin-dependent protein
kinases (CaMK), and the extracellularly regulated protein
kinases (ERK) 1 and 2 [68] (Fig. 3b). Of all of these,
AMPK, PKD and CaMK have been studied for their effects
on metabolic processes.
AMPK is a heterotrimer consisting of a catalytic
a-domain, a glycogen-binding regulatory b-domain and an
AMP-binding regulatory c-domain. Binding of AMP to the
regulatory c-subunit of AMPK leads to a conformational
change of the kinase, which makes it accessible for
upstream AMPK kinases (AMPKK). These phosphorylate
AMPK at threonine-172 and consequently activate this
kinase. In the heart, activation of the a2 isoform of AMPK
is essential for contraction-induced GLUT4 and CD36
translocation [69]. Kinases with suggested AMPKK
activity include CaMK-kinase (CaMKK) and the tumor
suppressor protein LKB1 [70]. In LKB1-null mice con-
traction-induced GLUT4 and CD36 translocation are
completely abrogated, indicating that LKB1 is essential for
both translocation processes [69]. Additionally, LKB1 is
involved in hypoxia-induced AMPK-mediated cardiac
GLUT4 translocation [71].
CaMK-kinase (CaMKK) is described as an alternative
upstream kinase of AMPK [72]. However, evidence for the
physiological importance of CaMKK in cardiomyocyte
metabolism is scarce. One study reported basal activity and
phosphorylation of AMPK in LKB1-deficient cells that
could be further stimulated by calcium ionophores [72].
Another study, in which CaMKKb was overexpressed or
pharmacologically inhibited, showed that AMPK can also
be activated by CaMKK [73]. In addition, it was shown
that CaMKK is important for contraction-mediated GLUT4
and CD36 translocation in skeletal muscle [74]. However,
insulin
Contraction
(A) Insulin-mediated signalling
(B) Contraction-mediated signalling
IRS PI3K PIP3 PDK1/2
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Fig. 3 signaling proteins involved in insulin-stimulated (a) and
contraction-stimulated (b) induction of GLUT4 and CD36 trafficking.
a Upon binding of insulin to its receptor the downstream signaling
axis (Akt axis) will be activated which induces the translocation of
intracellular GLUT4 and CD36 vesicles. This signaling axis consists
of insulin receptor substrate (IRS), phosphatidylinositol-3-kinase
(PI3K), PI-3-phosphate (PIP3), 3-phosphoinositide-dependent protein
kinase (PDK), protein kinase C (PKC) and Akt. b Cardiac work
increases the AMP/ATP-ratio and, subsequently, AMP-activated
protein kinase (AMPK) activity. For full activation the action of
upstream kinases, LKB1 or CaMKK, are warranted. Downstream, and
alongside, of AMPK, ERK1/2, PKC and PKD are other players in
GLUT4 and CD36 translocation. For figure simplicity, GLUT4 and
CD36 are drawn in one transport compartment while we know that
they are present in several different compartments
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the importance of CaMKK in cardiac GLUT4 and CD36
translocation remains to be established.
Downstream events of AMPK involve atypical PKCs,
ERK1/2, TBC1D1 and TBC1D4. It was shown that exer-
cise increases glucose transport in skeletal muscle via
AMPK through atypical PKCs. Furthermore, these effects
of atypical PKCs were dependent on the ERK1/2 pathway,
activation of proline-rich tyrosine kinase-2 (PYK2), and
phospholipase D (PLD) [75]. In a muscle-specific knockout
mouse model for the atypical PKC PKCk, glucose transport
was impaired and mice developed the metabolic syndrome
[76]. In rat skeletal muscle, ERK1/2 inhibitors decreased
contraction-induced fatty acid uptake and CD36 translo-
cation [77]. Hence, atypical PKCs and ERKs are involved
in contraction-stimulated substrate uptake in skeletal
muscle. However, their function in substrate uptake of the
heart still needs to be disclosed.
We recently identified involvement of the contraction-
activated protein PKD to be involved in contraction-induced
GLUT4 translocation and glucose uptake [78]. Pharmaco-
logical inhibition of PKD1 in cardiomyocytes inhibited
contraction-stimulated GLUT4 translocation and glucose
uptake [78]. Furthermore, contraction-stimulated PKD1
activation was still able to induce GLUT4 translocation and
glucose uptake in AMPKa2 knockout mice suggesting that
PKD1 acts independently of AMPK [78]. These findings
suggest that contraction-mediated translocation of GLUT4 is
a dual input mechanism which needs both the input of AMPK
and PKD. Future experiments should reveal the role of PKD in
contraction-induced CD36 translocation and fatty acid
uptake. Additionally, upstream and downstream proteins of
PKD1 have not yet been elucidated.
Surprisingly, the two Akt substrates TBC1D1 and
TBC1D4 are also substrates of activated AMPK and
therefore also part of the contraction signaling cascade [66,
79]. Although these data suggest a complementary role of
both TBC1D isoforms, the high expression of TBC1D1 in
muscle compared to fat tissue indicates a pivotal role of
this protein in contractile tissue [79]. Still, further research
is needed to unravel (1) whether the two isoforms are
physiologically relevant, and (2) whether they fulfil similar
functions in CD36 translocation.
In summary, GLUT4 and CD36 translocation seem
identically regulated by increased workload, but the roles
of CaMKK and PKD in contraction-induced CD36 trans-
location still await exploration.
Trafficking machinery involved in GLUT4 and CD36
translocation
The trafficking machinery involved in GLUT4 transloca-
tion [45, 80–85], especially in adipocytes and muscle cells,
has gained much more attention than the trafficking
machinery involved in CD36 translocation [4, 5]. The
isolation of GLUT4 vesicles revealed approximately 50
proteins that regulate vesicle fission, -transport and -fusion,
as well as the specificity of GLUT4 transport [86]. CD36-
containing vesicles have been isolated [16], but not so far
extensively studied with a proteomics approach.
Cellular protein traffic generally involves three major
steps. Firstly, vesicle fission: at the donor compartment, the
membranes will be curved into a bud that will subsequently
excise. This process is dependent on bilayer destabilizing
proteins, coat proteins, Rab GTPases and a number of
adaptor proteins forming a fission complex. Secondly,
subcellular vesicle transport: these newly formed transport
vesicles move along one of the cytoskeletal networks with
the aid of motor proteins which are regulated by Rab
GTPases. And thirdly, vesicle fusion: at the acceptor
compartment, the vesicle membranes fuse with the accep-
tor lipid bilayer requiring the formation of a SNARE
complex and is modulated by Rab GTPases. Both trans-
location and endocytotic routes between endosomes and
the sarcolemma proceed accordingly (Figs. 1, 4).
Although it is generally believed that GLUT4 and CD36
translocation are vesicle-mediated endosomal processes,
GLUT4 localization overlaps only for 30–40% with mark-
ers of this endocytosis system, e.g., the transferrin receptor
and Rabs. In addition, chemical ablation of endosomes does
not fully block insulin-stimulated GLUT4 translocation in
adipocytes [87].
Recently, posttranslational modification of GLUT4 by
ubiquitination was found to be important for its intracel-
lular sorting [88]. CD36 can also be ubiquitinated, but in
this case ubiquitination affects protein expression rather
than localization [89].
Recent data, which will be discussed below, have
revealed the role of these trafficking components in GLUT4
and CD36 translocation.
Coat proteins
Coat proteins are essential players in vesicle fission and
fusion. To inititate vesicle fission, these proteins are
recruited to membrane spots where cargo is concentrated
by adaptor proteins. There, coat proteins form a ‘bulb’ in
the membrane and thus start budding of a vesicle. Once the
vesicle is formed and detached from the organelle, the coat
proteins are released. The following protein families are
known to function as coat proteins: coat protein complex
(COP), clathrin and caveolin, which reside in specific
subcellular compartments [15, 90].
COPI and II are involved in transport from the ER to the
Golgi apparatus, where sorting receptors couple specific
cargo to COPI and COPII transport vesicles [15, 91]. Much
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of the knowledge on COPI vesicle formation is derived
from pharmacological studies using brefeldin-A as a non-
competitive inhibitor of Arf1 [92, 93], although it has also
been reported that brefeldin-A affects clathrin functioning
[94]. Treatment of cells with brefeldin-A results in rapid
fusion of the Golgi apparatus with the ER, which suggests
an important role of these coat proteins in the maintenance
of the distinct organelles [92]. However, the use of bre-
feldin-A in rat adipocytes could not clearly prove an
involvement of COPI in insulin-stimulated GLUT4 trans-
location to the plasma membrane [95–98]. Studies
performed in cardiomyocytes show that COP proteins and/
or clathrin function in stimulus-induced glucose and fatty
acid uptake in cardiomyocytes [4]. Hence, GLUT4 and
CD36 translocation in cardiomyocytes are both closely
related vesicle-mediated processes (Figs. 1, 4).
Caveolins—caveolin-1, -2 and -3—reside in cholesterol-
enriched lipid rafts of the plasma membrane called cave-
olae. Caveolins could play a role in plasmalemmal docking
of GLUT4- or CD36-containing vesicles, and could be
involved in GLUT4 or CD36 internalization [99, 100].
Caveolin-1 [101, 102] has been proposed to play a role in
initiation of GLUT4 endocytosis in adipocytes, but in
skeletal muscle, the muscle-specific isoform caveolin-3
does not colocalize with GLUT4 [103]. Hence, the role of
caveolins in GLUT4 trafficking is unclear. Caveolin-1 has
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Fig. 4 Signaling-pathways and
subcellular trafficking
components involved in GLUT4
and CD36 translocation in
cardiomyocytes. a Basal
recycling: during basal
recycling of endosomal vesicles
GLUT4 is directed towards an
insulin-responsive GLUT4
specific vesicle compartment
which also contains IRAP. Coat
proteins and the transferrin
receptor are found in GLUT4
and CD36 vesicles in the
endosomal compartment.
V-ATPase is only involved in
basal recycling of CD36
containing vesicles. b insulin-
mediated translocation (Akt-
axis): insulin releases the
vesicles from the inhibitory
action of TBC1D1/4 and acts on
VAMP2 containing GLUT4 and
CD36 vesicles. V-ATPase is
only involved in insulin-
mediated GLUT4 translocation
and c contraction-mediated
translocation (AMPK-axis):
contraction also affects
functioning of TBC1D1/4.
Furthermore, VAMP3 is
involved in contraction-
mediated translocation of
GLUT4 and CD36
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been shown to be involved in CD36 localization and
function in smooth muscle cells [104] and fibroblast [105].
However, caveolin-3 does not seem to play a role in CD36
translocation in muscle cells because regulation of cardiac
LCFA uptake was not altered in caveolin-3 knockout mice.
In conclusion, there is evidence that caveolin-1 is involved
in GLUT4 and CD36 translocation in non-muscle cells, but
caveolin-3 most likely does not play a role in translocation
of both transporters in (cardiac) myocytes.
Cytoskeletal filaments
It is well established that reorganization of filamentous actin
beneath the plasma membrane plays a role in insulin-
induced GLUT4 translocation [83, 106–108]. Insulin sig-
naling bifurcates at the level of PI3K towards Akt and Rac.
Insulin activates GTP loading of Rac within 5 min and then
induces reorganization of actin. It has been shown that
agents that disturb actin polymerization, e.g., latrunculin
B or cytochalasin D, inhibit insulin-induced GLUT4
translocation in adipocytes, skeletal muscle cells and
cardiomyocytes [4, 82, 83, 109]. Findings obtained by
these pharmacological approaches were confirmed by
overexpression of a dominant negative Rac mutant [110] or
siRNA-mediated knockdown of Rac [111]. Recently, it was
shown that Arp2/3 is a downstream effector of Rac and
that cofilin regulates actin depolymerization which again
proposes that active actin cycling is essential for insulin-
stimulated GLUT4 translocation [83]. In contrast, latrun-
culin B did not inhibit stimulus-induced CD36 translocation
in cardiomyocytes [4]. Hence, actin filaments are involved
in GLUT4 translocation, but not in CD36 translocation in
the heart.
Microtubule involvement in GLUT4 translocation has
mainly been studied in adipocytes. Controversy exists
about their role in stimulus-induced GLUT4 transloca-
tion. Some groups reported that microtubule-disrupting
agents inhibited insulin-induced GLUT4 translocation in
3T3-adipocytes [81, 112], while others did not find any
effect on this process [113]. However, microtubules do
not seem to play a role in stimulus-induced GLUT4 or
CD36 translocation in skeletal muscle and cardiomyo-
cytes [4, 114].
Although the cytoskeleton is clearly involved in GLUT4
and CD36 translocation in cardiomyocytes, its role in the
altered transporter localization in diabetes has not yet been
studied. However, investigators in other fields of research
have studied the cytoskeleton in the diabetic heart. For
example, in ventricular cells from streptozotocin-induced
diabetic rats, impairment of cytoskeletal function and
structure—actin and microtubules—was found. In their
study, the insulin-deficient conditions affected the cardiac
potassium-current in a cytoskeleton-dependent manner
[115], suggesting that this may also affect insulin-depen-
dent GLUT4 translocation.
Endosomal pH
The acidity of intracellular compartments, such as endo-
somes, is essential for various cellular processes, including
endosomal function and vesicular trafficking [116, 117].
Endosomal acidification is regulated by vacuolar-ATPase
(v-ATPase or V1V0-ATPase), a large multisubunit com-
plex that functions as an ATP-driven proton pump. It has a
similar build-up as the F1F0-ATPase located at the mito-
chondrial membrane; however, it needs ATP to pump
protons whereas the F1F0 needs protons to produce ATP
[118].
Surprisingly, not much is known about the role of
endosomal acidity in trafficking of GLUT4 or CD36. The
role of v-ATPases in GLUT4 translocation has been stud-
ied in 3T3-L1 adipocytes [119], and in cardiomyocytes
[120]. Upon inhibition of v-ATPase with bafilomycin A1 in
3T3-L1 adipocytes, insulin-stimulated glucose uptake was
disrupted and GLUT4 accumulated in intracellular mem-
branes, while Akt and IRS1 signaling were still intact.
From these data, it was concluded that proper regulation of
endosomal pH is important for the formation of small
insulin-responsive vesicles [119]. This has also been
studied in cardiomyocytes, and in these cells, v-ATPases in
the GLUT4-containing vesicles may play a role in insulin-
stimulated increase of GLUT4 translocation and glucose
uptake [120, 121]. When examining GLUT1 in mouse
mammary epithelial cells, it was found that endosomal
acidification was important for directed trafficking of
GLUT1 [122].
We recently used the specific v-ATPase inhibitor
bafilomycin-A and the proton ionophore monensin to study
the role of endosomal acidification in CD36 translocation.
While reducing glucose uptake only in the acutely stimu-
lated state, both compounds already increased basal CD36
translocation and subsequent fatty acid uptake [4]. Thus,
v-ATPase seems to be involved in stimulus-induced, but
not in basal, GLUT4 translocation. This seems to be
opposite for CD36 translocation, where v-ATPase is
involved in basal, but not in stimulus-induced, processes
(Figs. 4 and 5). A novel function of v-ATPase is the
modulation of protein traffic between early and late
endosomes. Here, vATPase acts as a pH sensor interacting
with proteins such as small GTPases of the Arf-family and
their regulatory proteins [123]. Whether this function of
the v-ATPases is involved in GLUT4 and CD36 translo-
cation is not yet known. However, the proton pump
function of the v-ATPases is clearly important since
bafilomycin A and monensin similarly affect GLUT4 and
CD36 localization.
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Taken together, regulation of the endosomal pH seems
an interesting target to restore the metabolic substrate
balance in type 2 diabetes.
Rab proteins
Rab-GTPases are regulators of multiple steps of vesicular
transport (e.g., vesicle formation, transport along the actin-
and microtubule-based cytoskeleton and fusion with target
membranes) by facilitating the formation of SNARE
complexes [124, 125]. Therefore, Rab-GTPases are con-
sidered to play a key role in the control of GLUT4 and
CD36 vesicle trafficking [126]. Adding to the complexity,
19 isoforms of the more than 60 currently known Rabs are
present on GLUT4 vesicles [62]. Examples are Rab4 and
Rab11a, which are involved in the intracellular GLUT4
sequestration and endocytosis of both GLUT4 and CD36,
respectively [127–129]. Interestingly, Rab11a was acti-
vated and recruited to GLUT4 vesicles upon insulin
stimulation [130, 131]. In this context, it was also observed
that Rab11a shifted from microsomal fractions to the
plasma membrane after insulin stimulation. In addition,
Rab4 GTP-loading is also stimulated by insulin, and this
complex is known to bind syntaxin4, which functions in the
docking and fusion of vesicles with the plasma membrane
[132, 133]. Two proteins interacting with Rab11a, i.e.,
FIP2 and Rip11, have been investigated for their role in
GLUT4 and CD36 recycling. FIP2, which functions as an
adaptor for interaction of Rab11 with the motor protein
myosin-Vb [134], mediates endocytosis of both GLUT4
and CD36 in cardiac myoblast cultures [128]. In the same
cell system, Rip11, which colocalizes with Rab11 in
endosomal membranes [135], is involved in CD36 endo-
cytosis, but does not influence GLUT4 dynamics [128].
However, in cultured adipocytes, Rip11 does influence
GLUT4 traffic, indicating a cell type-specific function of
this Rab11a regulator [136].
Rab-GTPase activating proteins (Rab-GAPs) silence Rab
activity by keeping them in an inactive state [137]. TBC1D1
and TBC1D4, two proteins mentioned as Akt- and AMPK
substrates in ‘‘Signalling pathways involved in GLUT4 and
CD36 translocation’’, are Rab-GAPs that silence Rab-func-
tion on GLUT4 translocation [62, 138]. By doing so, they
restrain GLUT4 in its intracellular stores under basal condi-
tions. Insulin releases this brake on GLUT4 translocation by
stimulating Akt-mediated phosphorylation and inactivation of
TBC1D1 and 4. This will promote the formation of GLUT4
transport vesicles and eventually their translocation to the
plasma membrane [63, 139]. As detailed in ‘‘Contraction-
signaling’’, under conditions of increased contractions, acti-
vated AMPK acts analogous to Akt, indicating a common
mechanism of GLUT4 mobilization that is shared by different
signaling pathways [140]. Which Rab isoforms are regulated
by TCB1D1 and TBC1D4, respectively? In vitro Rab-GAP
assays revealed a strong activity of both GAPs against Rab2a,
-8, -10 and -14, and no activity against the above-mentioned
Rab4 and Rab11a [62, 63]. Still, identifying one Rab protein to
be the crucial isoform for GLUT4 translocation remains
challenging, as Rab8a, -10 and -13 all appear to be essential
for complete insulin-dependent GLUT4 translocation to
plasma membrane [141–143]. In addition, if and how
TBC1D1, TBC1D4 and Rabs are involved in CD36 translo-
cation needs further study.
SNARE proteins
Integration of vesicular GLUT4 and CD36 into the plasma
membrane is regulated by soluble N-ethylmaleimide-sen-
sitive factor attachment protein receptors (SNAREs), the
mechanistic core complexes of membrane fusion [144].
Subtypes of the SNARE proteins have been classified
depending on the amino acid residue within the SNARE
motifs which is either a glutamine (Q-SNAREs) or an
arginine (R-SNAREs) [145]. When the vesicle-associated
R-SNAREs interact with a specific subset of Q-SNAREs at
the target membrane, a hetero-oligomeric SNARE complex
is formed which catalyzes the fusion of the vesicle with the
target membrane [145].
none
+Monensin (Mon)
+Bafilomycin (Baf)
Surface GLUT4
C Mon Baf
0
1
2
3
4
*
*
M
ul
tip
le
 o
f c
on
tro
l
C Mon Baf
0.0
0.5
1.0
1.5
M
ul
tip
le
 o
f c
on
tro
l
Surface CD36
Fig. 5 Endosomal pH is
important for cardiomyocyte
transporter translocation.
Isolated rat cardiomyocytes
were treated with pH gradient
disturbing agents, monensin
(Mon) and bafilomycin A (Baf).
Afterwards, GLUT4 and CD36
presence at the cell surface were
assayed. During basal recycling,
disturbance of the pH gradient
only affects CD36 translocation
[4]
Regulation of substrate transporter trafficking 2533
123
It is well accepted that insulin-stimulated translocation
of GLUT4 in adipocytes, skeletal- and cardiac myocytes
involves the R-SNARE VAMP2 [146], which interacts
with the Q-SNAREs syntaxin4 and SNAP23 at the plasma
membrane (Fig. 4) [147, 148]. We have recently shown
that insulin-stimulated CD36 translocation is also depen-
dent on VAMP2 [5]. Another VAMP isoform, VAMP3,
links contraction signaling to GLUT4 and CD36 translo-
cation, disclosing a strong resemblance of the mechanisms
of GLUT4 and CD36 trafficking [5]. Although present on
GLUT4 vesicles, VAMP3 does not translocate to the
plasma membrane upon increased contraction, pointing to a
rather unclear function of this VAMP isoform in GLUT4
translocation [149]. However, other VAMP isoforms, like
VAMP4 and VAMP7, are differentially involved in the
regulation of GLUT4 and CD36 traffic and could be the
basis for selective regulation of transporter distribution [5].
Still, their physiological function needs to be disclosed.
Concluding remarks
A complex interplay between signaling pathways and traf-
ficking components is involved in the regulation of GLUT4
and CD36 translocation (Fig. 4). The signaling pathways
appear to similarly affect GLUT4 and CD36 translocation
and thus are unsuitable targets for restoring the improper
subcellular localization of both substrate transporters in the
diabetic heart, for example by bringing GLUT4 to the cell
surface and internalizing CD36. However, the subcellular
trafficking machinery is able to discriminate between reg-
ulation of GLUT4 and CD36 translocation, and therefore
could form the basis of a novel approach to restore cardiac
substrate preference in metabolic diseases with altered
substrate utilization. Coat proteins are similarly involved in
GLUT4 and CD36 translocation. Other trafficking compo-
nents are differentially involved in both processes. In detail,
actin organisation and v-ATPase are specifically involved
in GLUT4 translocation, while v-ATPase is specifically
involved in CD36 endocytosis. Future experiments should
explore the possible disturbance of these subcellular traf-
ficking components in animal models and in biopsies from
patients with type 2 diabetes.
Importantly, all these trafficking components that dif-
ferentiate between GLUT4 and CD36 translocation are
novel targets for the development of therapies to restore the
metabolic balance in cardiomyocytes during disease char-
acterized by unbalanced substrate usage (e.g., insulin
resistance, diabetic cardiomyopathy and heart failure).
Another advantage in therapeutically targeting the GLUT4
and CD36 trafficking machineries is that this can be
achieved in a tissue-specific manner because many mem-
bers of the major trafficking protein families display a
tissue-specific distribution pattern [144, 150]. Future
research will undoubtedly unmask more GLUT4 and
CD36-dedicated trafficking proteins that could be added to
the list of novel anti-diabetic targets.
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